Performance of Biotech IPOs Relative to Cash on Hand
This article was originally published in Start Up
Executive Summary
While the majority of the biotech IPO class of 2000 have plummeted from their highs, some continue to do comparatively well. To add an extra dimension to tracking the performance of these biotechs since their IPOs, we've plotted the ten companies with the most cash on hand post-IPO against a group with the least to see if those companies with stronger cash positions were better able than their peers to survive the current bear market.
You may also be interested in...
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
A Learning Lab For Outcomes-Based Risk-Sharing Agreements
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.